

Supplementary file 4: CT values for in PCR.

Figure	Cell	Plasmid transfection/cell treatment	Gene	CT values		
Fig. 1A	JEG3	Control	miR-218-1-3p	27.53	27.73	27.79
	HTR-8	Control	miR-218-1-3p	26.48	26.49	26.71
	JEG3	TCS	miR-218-1-3p	25.43	25.6	25.24
	HTR-8	TCS	miR-218-1-3p	23.48	23.1	23.36
	JEG3	Control	U6	18.89	18.96	19.47
	HTR-8	Control	U6	18.05	18.11	18.46
	JEG3	TCS	U6	19.61	18.65	18.68
HTR-8	TCS	U6	18	17.74	17.71	
Fig. 1B	JEG3	NC mimics	miR-218-1-3p	27.75	27.45	27.66
	HTR-8	NC mimics	miR-218-1-3p	26.21	26.21	26.41
	JEG3	miR-218-1-3p mimics	miR-218-1-3p	25.05	24.84	24.71
	HTR-8	miR-218-1-3p mimics	miR-218-1-3p	23.85	23.43	23.54
	JEG3	NC mimics	U6	19.02	19.36	18.94
	HTR-8	NC mimics	U6	18.38	18.03	17.51
	JEG3	miR-218-1-3p mimics	U6	18.8	19.09	18.66
HTR-8	miR-218-1-3p mimics	U6	17.53	17.81	17.58	
Fig. 1E	JEG3	NC mimics	IL-6	23.34	23.36	23.84
	HTR-8	NC mimics	IL-6	23.18	23.52	23.21
	JEG3	miR-218-1-3p mimics	IL-6	22.77	22.46	22.36
	HTR-8	miR-218-1-3p mimics	IL-6	22.12	22.45	22.26
	JEG3	NC mimics	GAPDH	19.66	19.43	18.94
	HTR-8	NC mimics	GAPDH	17.89	18.8	18.75
	JEG3	miR-218-1-3p mimics	GAPDH	19.2	19.9	19.44
HTR-8	miR-218-1-3p mimics	GAPDH	17.85	18.55	18.26	
Fig. 1F	JEG3	NC mimics	IL-1 $\beta$	23.57	23.95	23.9
	HTR-8	NC mimics	IL-1 $\beta$	21.6	21.43	21.37
	JEG3	miR-218-1-3p mimics	IL-1 $\beta$	22.19	22	21.77
	HTR-8	miR-218-1-3p mimics	IL-1 $\beta$	20.35	20.08	19.96
	JEG3	NC mimics	GAPDH	19.92	19.44	19.36
	HTR-8	NC mimics	GAPDH	18.76	18.5	17.95
	JEG3	miR-218-1-3p mimics	GAPDH	18.93	19.25	19.37
HTR-8	miR-218-1-3p mimics	GAPDH	17.84	18.83	17.89	
Fig. 1G	JEG3	NC mimics	TNF- $\alpha$	24.28	24.12	24.39
	HTR-8	NC mimics	TNF- $\alpha$	22.12	22.53	22.12
	JEG3	miR-218-1-3p mimics	TNF- $\alpha$	22.15	22.28	21.96
	HTR-8	miR-218-1-3p mimics	TNF- $\alpha$	21.49	21.07	21.26
	JEG3	NC mimics	GAPDH	19.86	19.37	19.26
	HTR-8	NC mimics	GAPDH	18.65	18.31	18.46
	JEG3	miR-218-1-3p mimics	GAPDH	19.39	18.95	19.29
HTR-8	miR-218-1-3p mimics	GAPDH	18.73	18.76	18.55	
Fig. 1H	JEG3	NC mimics	CXCL-8	24.86	25.02	24.81
	HTR-8	NC mimics	CXCL-8	23.84	23.65	23.77
	JEG3	miR-218-1-3p mimics	CXCL-8	23.44	23.79	23.63
	HTR-8	miR-218-1-3p mimics	CXCL-8	22.21	22.29	22.56
	JEG3	NC mimics	GAPDH	19.16	19.06	19.29
	HTR-8	NC mimics	GAPDH	18.12	18.69	18.43
	JEG3	miR-218-1-3p mimics	GAPDH	19.59	19.69	19.35
HTR-8	miR-218-1-3p mimics	GAPDH	18.61	18.15	18.7	
Fig. 2F	JEG3	pcDNA3.1	miR-218-1-3p	26.81	26.83	27.08
	HTR-8	pcDNA3.1	miR-218-1-3p	26.12	26.28	26.1
	JEG3	pcDNA3.1-JUN	miR-218-1-3p	24.75	24.78	25.11
	HTR-8	pcDNA3.1-JUN	miR-218-1-3p	24.52	24.48	24.8
	JEG3	pcDNA3.1	U6	19.4	19.38	19.55
	HTR-8	pcDNA3.1	U6	17.95	17.65	18.45
	JEG3	pcDNA3.1-JUN	U6	19.52	19.34	19.02
HTR-8	pcDNA3.1-JUN	U6	17.56	18.28	18.36	
Fig. 2I	JEG3	Control	miR-218-1-3p	26.87	26.89	27.1
	HTR-8	Control	miR-218-1-3p	27.17	26.83	26.66
	JEG3	TCS	miR-218-1-3p	25.04	25.15	24.75
	HTR-8	TCS	miR-218-1-3p	25.14	24.72	24.87
	JEG3	TCS+sh-JUN	miR-218-1-3p	26.87	26.66	26.98
	HTR-8	TCS+sh-JUN	miR-218-1-3p	26.71	26.54	26.31
	JEG3	Control	U6	19.09	18.78	19.4
	HTR-8	Control	U6	17.68	18.42	18.23
	JEG3	TCS	U6	19.5	18.97	19.46
	HTR-8	TCS	U6	18.12	18.07	18.05
	JEG3	TCS+sh-JUN	U6	18.9	19.61	18.7
HTR-8	TCS+sh-JUN	U6	17.83	17.86	17.6	
Figure 3A	JEG3	Control	PSME3	24.44	24.49	24.6
	JEG3	TCS	PSME3	25.03	25.3	25.12
	JEG3	Control	HOXA11	24.47	24.3	24.09
	JEG3	TCS	HOXA11	23.65	23.95	23.85
	JEG3	Control	CD8B	22.92	22.91	22.69
	JEG3	TCS	CD8B	23.53	23.18	23.42
	JEG3	Control	HK1	23.76	23.74	24.01
JEG3	TCS	HK1	23.98	24.2	24.38	

Figure 3A	JEG3	Control	GALP	22.47	22.57	22.38	
	JEG3	TCS	GALP	22.58	22.87	22.8	
	JEG3	Control	HIST1H2AI	24.55	24.65	24.76	
	JEG3	TCS	HIST1H2AI	24.71	25.14	25.03	
	JEG3	Control	SLC35C1	21.29	21.43	21.25	
	JEG3	TCS	SLC35C1	23.33	23.66	24.13	
	JEG3	Control	GAPDH	19.57	19.17	19.39	
	JEG3	TCS	GAPDH	19.88	19.54	19.64	
Figure 3B	HTR-8	Control	CD8B	25.11	25.1	24.82	
	HTR-8	TCS	CD8B	25.09	25.38	25.14	
	HTR-8	Control	SLC35C1	24.07	23.79	24.13	
	HTR-8	TCS	SLC35C1	25.35	25.72	25.62	
	HTR-8	Control	GAPDH	18.57	17.96	18.48	
	HTR-8	TCS	GAPDH	18.06	18.23	18.56	
Figure 3D	JEG3	NC mimics	SLC35C1	21.93	22.08	22.13	
	HTR-8	NC mimics	SLC35C1	23.51	23.63	23.66	
	JEG3	miR-218-1-3p mimics	SLC35C1	24.03	24.19	24.29	
	HTR-8	miR-218-1-3p mimics	SLC35C1	25.22	25.16	25.46	
	JEG3	NC mimics	GAPDH	19.37	19.68	19.43	
	HTR-8	NC mimics	GAPDH	17.84	18.73	18.55	
	JEG3	miR-218-1-3p mimics	GAPDH	19.13	19.18	19.61	
	HTR-8	miR-218-1-3p mimics	GAPDH	18.45	17.9	17.93	
Figure 3E (原 Figure 3F)	JEG3	NC inhibitor	SLC35C1	21.19	21.38	21.13	
	HTR-8	NC inhibitor	SLC35C1	23.93	23.94	24.11	
	JEG3	miR-218-1-3p inhibitor	SLC35C1	18.13	17.89	18.22	
	HTR-8	miR-218-1-3p inhibitor	SLC35C1	22.11	22.03	22.38	
	JEG3	NC inhibitor	GAPDH	19.66	19.57	19.87	
	HTR-8	NC inhibitor	GAPDH	17.95	18.59	18.41	
	JEG3	miR-218-1-3p inhibitor	GAPDH	19.07	18.94	19.35	
	HTR-8	miR-218-1-3p inhibitor	GAPDH	18.25	17.85	18.76	
Figure 4A	JEG3	sh-NC	SLC35C1	22.01	21.61	21.94	
	HTR-8	sh-NC	SLC35C1	23.77	24.28	24.1	
	JEG3	sh-SLC35C1#1	SLC35C1	24.35	24.08	23.94	
	HTR-8	sh-SLC35C1#1	SLC35C1	25.83	25.48	25.8	
	JEG3	sh-SLC35C1#2	SLC35C1	23.4	23.03	23.28	
	HTR-8	sh-SLC35C1#2	SLC35C1	25.48	25.19	25.43	
	JEG3	sh-NC	GAPDH	19.51	19.77	19.44	
	HTR-8	sh-NC	GAPDH	18.14	18.09	18.48	
	JEG3	sh-SLC35C1#1	GAPDH	19.14	19.59	19.75	
	HTR-8	sh-SLC35C1#1	GAPDH	18.31	18.3	17.88	
	JEG3	sh-SLC35C1#2	GAPDH	19.52	19.64	19.07	
	HTR-8	sh-SLC35C1#2	GAPDH	18.13	18.7	18.39	
	Fig. 4D	JEG3	sh-NC	IL-6	23.18	23.16	23.33
		HTR-8	sh-NC	IL-6	22.53	22.7	22.78
JEG3		sh-SLC35C1#1	IL-6	22.56	22.29	22.59	
HTR-8		sh-SLC35C1#1	IL-6	21.94	21.73	21.53	
JEG3		sh-NC	GAPDH	19.74	18.98	19.44	
HTR-8		sh-NC	GAPDH	18.78	18.42	17.97	
JEG3		sh-SLC35C1#1	GAPDH	19.39	19.88	19.68	
HTR-8		sh-SLC35C1#1	GAPDH	18.45	18.79	18.04	
JEG3		sh-NC	IL-1 $\beta$	24.03	24.48	24.34	
HTR-8		sh-NC	IL-1 $\beta$	22.27	21.93	21.91	
JEG3		sh-SLC35C1#1	IL-1 $\beta$	23.35	23.12	23.38	
HTR-8		sh-SLC35C1#1	IL-1 $\beta$	20.69	20.94	20.54	
JEG3		sh-NC	GAPDH	19.8	19.63	19.5	
HTR-8		sh-NC	GAPDH	18.25	18.15	17.97	
JEG3		sh-SLC35C1#1	GAPDH	19.73	19.75	19.45	
HTR-8		sh-SLC35C1#1	GAPDH	18.28	18.34	17.96	
JEG3		sh-NC	TNF- $\alpha$	23.6	23.79	23.93	
HTR-8		sh-NC	TNF- $\alpha$	22.7	22.52	22.82	
JEG3		sh-SLC35C1#1	TNF- $\alpha$	21.76	21.98	22.11	
HTR-8		sh-SLC35C1#1	TNF- $\alpha$	20.29	20.61	20.39	
JEG3		sh-NC	GAPDH	19.69	19.08	19.4	
HTR-8		sh-NC	GAPDH	18.37	18.04	18.37	
JEG3		sh-SLC35C1#1	GAPDH	19.68	19.57	19.84	
HTR-8		sh-SLC35C1#1	GAPDH	18.13	17.93	18.33	
JEG3		sh-NC	CXCL-8	24.36	24.38	24.09	
HTR-8		sh-NC	CXCL-8	22.88	23.01	23.04	
JEG3		sh-SLC35C1#1	CXCL-8	22.45	22.71	22.8	
HTR-8		sh-SLC35C1#1	CXCL-8	20.93	21.25	21.13	
JEG3		sh-NC	GAPDH	19.34	19.3	19.87	
HTR-8		sh-NC	GAPDH	18.01	18.19	18.48	
JEG3		sh-SLC35C1#1	GAPDH	18.97	19.8	19.27	
HTR-8		sh-SLC35C1#1	GAPDH	17.89	18.48	18.07	
JEG3		Control	SLC35C1	22.17	22.04	21.98	
HTR-8		Control	SLC35C1	23.83	24.06	24	
JEG3		TCS	SLC35C1	24.05	24.38	24.44	
HTR-8		TCS	SLC35C1	25.62	25.93	25.96	
JEG3		TCS+miR-218-1-3p inhibitor	SLC35C1	22.57	22.5	22.79	

Fig. 5A	HTR-8	TCS+miR-218-1-3p inhibitor	SLC35C1	24.05	24.36	24.25
	JEG3	TCS+miR-218-1-3p inhibitor+sh-SLC35C1#1	SLC35C1	24.18	24.08	23.8
	HTR-8	TCS+miR-218-1-3p inhibitor+sh-SLC35C1#1	SLC35C1	25.8	25.51	25.42
	JEG3	Control	GAPDH	19.24	19.05	19.49
	HTR-8	Control	GAPDH	18.66	18.66	17.85
	JEG3	TCS	GAPDH	19.42	19	19.31
	HTR-8	TCS	GAPDH	18.13	18.51	18.47
	JEG3	TCS+miR-218-1-3p inhibitor	GAPDH	19.85	19.84	19.42
	HTR-8	TCS+miR-218-1-3p inhibitor	GAPDH	18.64	18.77	18.4
	JEG3	TCS+miR-218-1-3p inhibitor+sh-SLC35C1#1	GAPDH	19.64	19.5	19.51
	HTR-8	TCS+miR-218-1-3p inhibitor+sh-SLC35C1#1	GAPDH	18.67	17.93	18.14
Fig. 5D	JEG3	Control	IL-6	23.84	23.63	23.77
	HTR-8	Control	IL-6	22.9	22.37	22.66
	JEG3	TCS	IL-6	22.39	22.14	22.07
	HTR-8	TCS	IL-6	22	22.37	22.18
	JEG3	TCS+miR-218-1-3p inhibitor	IL-6	23.28	23.53	23.64
	HTR-8	TCS+miR-218-1-3p inhibitor	IL-6	22.77	22.97	23.08
	JEG3	TCS+miR-218-1-3p inhibitor+sh-SLC35C1#1	IL-6	21.93	22.15	22.25
	HTR-8	TCS+miR-218-1-3p inhibitor+sh-SLC35C1#1	IL-6	21.76	22.05	21.87
	JEG3	Control	GAPDH	19.89	19.64	19.49
	HTR-8	Control	GAPDH	18.06	18.09	18.27
	JEG3	TCS	GAPDH	19.2	19.85	19.3
	HTR-8	TCS	GAPDH	18.55	18.47	18.45
	JEG3	TCS+miR-218-1-3p inhibitor	GAPDH	19.87	19.03	19.33
	HTR-8	TCS+miR-218-1-3p inhibitor	GAPDH	17.9	18.65	18.64
	JEG3	TCS+miR-218-1-3p inhibitor+sh-SLC35C1#1	GAPDH	19.28	19.74	19.15
HTR-8	TCS+miR-218-1-3p inhibitor+sh-SLC35C1#1	GAPDH	18.59	18.06	17.99	
Fig. 5E	JEG3	Control	IL-1 $\beta$	23.71	23.9	23.91
	HTR-8	Control	IL-1 $\beta$	22.37	22	22.03
	JEG3	TCS	IL-1 $\beta$	22.78	23.08	22.84
	HTR-8	TCS	IL-1 $\beta$	21.16	20.96	21.35
	JEG3	TCS+miR-218-1-3p inhibitor	IL-1 $\beta$	23.58	23.74	23.4
	HTR-8	TCS+miR-218-1-3p inhibitor	IL-1 $\beta$	22.13	21.99	21.74
	JEG3	TCS+miR-218-1-3p inhibitor+sh-SLC35C1#1	IL-1 $\beta$	23.01	22.7	22.66
	HTR-8	TCS+miR-218-1-3p inhibitor+sh-SLC35C1#1	IL-1 $\beta$	21.26	21.56	21.34
	JEG3	Control	GAPDH	19.45	19.2	19.39
	HTR-8	Control	GAPDH	18.63	18.03	18.24
	JEG3	TCS	GAPDH	19.31	19.28	19.5
	HTR-8	TCS	GAPDH	18.08	18.48	18.02
	JEG3	TCS+miR-218-1-3p inhibitor	GAPDH	19.48	19.27	18.97
	HTR-8	TCS+miR-218-1-3p inhibitor	GAPDH	18	18.36	18.3
	JEG3	TCS+miR-218-1-3p inhibitor+sh-SLC35C1#1	GAPDH	19.45	19.35	18.95
HTR-8	TCS+miR-218-1-3p inhibitor+sh-SLC35C1#1	GAPDH	17.92	18.79	18.59	
Fig. 5F	JEG3	Control	TNF- $\alpha$	24.64	24.39	24.16
	HTR-8	Control	TNF- $\alpha$	22.65	22.78	22.99
	JEG3	TCS	TNF- $\alpha$	23.29	22.91	23.12
	HTR-8	TCS	TNF- $\alpha$	20.76	21.09	20.87
	JEG3	TCS+miR-218-1-3p inhibitor	TNF- $\alpha$	24.78	24.52	24.83
	HTR-8	TCS+miR-218-1-3p inhibitor	TNF- $\alpha$	22.6	22.99	22.65
	JEG3	TCS+miR-218-1-3p inhibitor+sh-SLC35C1#1	TNF- $\alpha$	22.81	22.42	22.67
	HTR-8	TCS+miR-218-1-3p inhibitor+sh-SLC35C1#1	TNF- $\alpha$	21.14	21.41	21
	JEG3	Control	GAPDH	19.33	19.14	18.95
	HTR-8	Control	GAPDH	18.07	18.64	18.27
	JEG3	TCS	GAPDH	19.61	19.42	19.82
	HTR-8	TCS	GAPDH	18.26	18.8	18.22
	JEG3	TCS+miR-218-1-3p inhibitor	GAPDH	19.83	19.39	19.46
	HTR-8	TCS+miR-218-1-3p inhibitor	GAPDH	18.51	18.54	17.89
	JEG3	TCS+miR-218-1-3p inhibitor+sh-SLC35C1#1	GAPDH	19.08	19.76	18.97
	HTR-8	TCS+miR-218-1-3p inhibitor+sh-SLC35C1#1	GAPDH	18.79	18.55	18.22
	JEG3	Control	CXCL-8	24.29	24.1	24.12
	HTR-8	Control	CXCL-8	23.18	23.2	22.99
JEG3	TCS	CXCL-8	22.65	22.27	22.4	
HTR-8	TCS	CXCL-8	21	20.98	21.37	

Fig. 5G	JEG3	TCS+miR-218-1-3p inhibitor	CXCL-8	23.95	24.3	24.03
	HTR-8	TCS+miR-218-1-3p inhibitor	CXCL-8	22.57	22.84	22.67
	JEG3	TCS+miR-218-1-3p inhibitor+sh-SLC35C1#1	CXCL-8	22.68	22.94	22.52
	HTR-8	TCS+miR-218-1-3p inhibitor+sh-SLC35C1#1	CXCL-8	20.99	21.22	21.24
	JEG3	Control	GAPDH	19.81	19.38	19.53
	HTR-8	Control	GAPDH	18.78	18.52	18.43
	JEG3	TCS	GAPDH	19.16	19.1	19.24
	HTR-8	TCS	GAPDH	17.85	18.48	18.81
	JEG3	TCS+miR-218-1-3p inhibitor	GAPDH	19.87	19.7	19.1
	HTR-8	TCS+miR-218-1-3p inhibitor	GAPDH	18.75	18.28	18.26
	JEG3	TCS+miR-218-1-3p inhibitor+sh-SLC35C1#1	GAPDH	19.16	19.52	19.8
HTR-8	TCS+miR-218-1-3p inhibitor+sh-SLC35C1#1	GAPDH	18.01	18.4	18.31	
Figure S1D	JEG3	Control	IL-6	24.22	23.86	23.67
	HTR-8	Control	IL-6	22.99	22.85	22.81
	JEG3	TCS	IL-6	23.44	23.25	23.09
	HTR-8	TCS	IL-6	22.93	22.67	22.53
	JEG3	Control	GAPDH	19.11	19.26	19.67
	HTR-8	TCS	GAPDH	18.55	18.48	18.43
Figure S1E	JEG3	Control	IL-1 $\beta$	23.93	23.95	23.72
	HTR-8	Control	IL-1 $\beta$	22.03	21.81	22.15
	JEG3	TCS	IL-1 $\beta$	22.79	22.92	23.15
	HTR-8	TCS	IL-1 $\beta$	21.07	20.76	21.11
	JEG3	Control	GAPDH	19.4	19.35	19.17
	HTR-8	TCS	GAPDH	18.53	18.4	18
Figure S1F	JEG3	Control	TNF- $\alpha$	24.2	23.95	24.26
	HTR-8	Control	TNF- $\alpha$	23.03	23.25	22.97
	JEG3	TCS	TNF- $\alpha$	22.38	22.6	22.21
	HTR-8	TCS	TNF- $\alpha$	21.96	22.29	21.99
	JEG3	Control	GAPDH	18.95	19.14	19.85
	HTR-8	TCS	GAPDH	18.19	18.78	18.83
Figure S1G	JEG3	Control	CXCL-8	24.9	24.8	25.09
	HTR-8	Control	CXCL-8	23.84	23.77	23.63
	JEG3	TCS	CXCL-8	23.25	22.87	22.9
	HTR-8	TCS	CXCL-8	22.62	22.71	22.36
	JEG3	Control	GAPDH	18.95	19.85	19.37
	HTR-8	TCS	GAPDH	18.34	18.02	18.24